CLGN
CollPlant Biotechnologies Ltd.
Biotechnology
Market Cap$5M
5Y Perf.-96.1%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
CLGN vs RGEN vs NTRA vs NVCR vs BEAM
Revenue, margins, valuation, and 5-year total return — side by side.
RGEN
Repligen Corporation
Medical - Instruments & Supplies
Market Cap$6.96B
5Y Perf.-5.7%
NTRA
Natera, Inc.
Medical - Diagnostics & Research
Market Cap$27.53B
5Y Perf.+343.0%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$2.04B
5Y Perf.-73.5%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.32B
5Y Perf.+26.5%
CLGN vs RGEN vs NTRA vs NVCR vs BEAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CLGN | RGEN | NTRA | NVCR | BEAM |
|---|---|---|---|---|---|
| Industry | Biotechnology | Medical - Instruments & Supplies | Medical - Diagnostics & Research | Medical - Instruments & Supplies | Biotechnology |
| Market Cap | $5M | $6.96B | $27.53B | $2.04B | $3.32B |
| Revenue (TTM) | $2M | $763M | $2.50B | $674M | $132M |
| Net Income (TTM) | $-12M | $51M | $-226M | $-173M | $-65M |
| Gross Margin | 25.1% | 51.5% | 65.2% | 75.2% | -64.2% |
| Operating Margin | -497.3% | 8.7% | -13.0% | -27.2% | -281.0% |
| Forward P/E | — | 61.7x | — | — | — |
| Total Debt | $3M | $690M | $214M | $290M | $294M |
| Cash & Equiv. | $12M | $566M | $1.08B | $103M | $295M |
CLGN vs RGEN vs NTRA vs NVCR vs BEAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CLGN
RGEN
NTRA
NVCR
BEAM
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| CollPlant Biotechno… (CLGN) | 100 | 3.9 | -96.1% |
| Repligen Corporation (RGEN) | 100 | 94.3 | -5.7% |
| Natera, Inc. (NTRA) | 100 | 443.0 | +343.0% |
| NovoCure Limited (NVCR) | 100 | 26.5 | -73.5% |
| Beam Therapeutics I… (BEAM) | 100 | 126.5 | +26.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CLGN vs RGEN vs NTRA vs NVCR vs BEAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RGEN leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Beam Therapeutics Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. CLGN also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
CLGN
CollPlant Biotechnologies Ltd.
The Income Pick
CLGN ranks third and is worth considering specifically for income & stability and sleep-well-at-night.
- beta 0.89
- Lower volatility, beta 0.89, Low D/E 22.9%, current ratio 4.44x
- Beta 0.89, current ratio 4.44x
- Beta 0.89 vs NVCR's 2.15, lower leverage
Best for: income & stability and sleep-well-at-night
RGEN
Repligen Corporation
The Value Play
RGEN carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- 6.7% margin vs CLGN's -491.3%
- 1.8% ROA vs CLGN's -86.3%, ROIC 2.2% vs -273.5%
Best for: value and quality
NTRA
Natera, Inc.
The Long-Run Compounder
NTRA is the clearest fit if your priority is long-term compounding.
- 18.3% 10Y total return vs RGEN's 358.2%
Best for: long-term compounding
NVCR
NovoCure Limited
The Healthcare Pick
Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.
Best for: healthcare exposure
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 120.0% revenue growth vs CLGN's -95.3%
- +87.4% vs CLGN's -77.9%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs CLGN's -95.3% |
| Value | RGEN | Better valuation composite |
| Quality / Margins | RGEN | 6.7% margin vs CLGN's -491.3% |
| Stability / Safety | CLGN | Beta 0.89 vs NVCR's 2.15, lower leverage |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | BEAM | +87.4% vs CLGN's -77.9% |
| Efficiency (ROA) | RGEN | 1.8% ROA vs CLGN's -86.3%, ROIC 2.2% vs -273.5% |
CLGN vs RGEN vs NTRA vs NVCR vs BEAM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
Segment breakdown not available.
Segment breakdown not available.
CLGN vs RGEN vs NTRA vs NVCR vs BEAM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRGENLAGGINGBEAM
Who Leads Where
RGEN leads in 2 of 6 categories
NTRA leads 1 • CLGN leads 0 • NVCR leads 0 • BEAM leads 0 • 2 tied
Explore the data ↓BEAMBeam Therapeutics Inc.
0leads
NVCRNovoCure Limited
0leads
CLGNCollPlant Biotechnolo…
0leads
NTRANatera, Inc.
1leads
RGENRepligen Corporation
2leads
6 Total Categories
CATEGORYLEADERvs NTRAvs CLGNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RGEN4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RGEN6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NTRA4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RGEN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NTRA is the larger business by revenue, generating $2.5B annually — 1010.5x CLGN's $2M. RGEN is the more profitable business, keeping 6.7% of every revenue dollar as net income compared to CLGN's -4.9%. On growth, CLGN holds the edge at +18.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CLGNCollPlant Biotech… | RGENRepligen Corporat… | NTRANatera, Inc. | NVCRNovoCure Limited | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $763M | $2.5B | $674M | $132M |
| EBITDAEarnings before interest/tax | -$11M | $155M | -$333M | -$165M | -$355M |
| Net IncomeAfter-tax profit | -$12M | $51M | -$226M | -$173M | -$65M |
| Free Cash FlowCash after capex | -$10M | $104M | $74M | -$48M | -$384M |
| Gross MarginGross profit ÷ Revenue | +25.1% | +51.5% | +65.2% | +75.2% | -64.2% |
| Operating MarginEBIT ÷ Revenue | -5.0% | +8.7% | -13.0% | -27.2% | -2.8% |
| Net MarginNet income ÷ Revenue | -4.9% | +6.7% | -9.0% | -25.7% | -49.2% |
| FCF MarginFCF ÷ Revenue | -4.0% | +13.7% | +3.0% | -7.1% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.3% | +14.8% | +38.8% | +12.3% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +28.9% | +50.0% | -20.0% | -100.0% | +26.6% |
RGEN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — CLGN and RGEN and NTRA and NVCR each lead in 1 of 4 comparable metrics.
Valuation Metrics
| Metric | CLGNCollPlant Biotech… | RGENRepligen Corporat… | NTRANatera, Inc. | NVCRNovoCure Limited | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| Market CapShares × price | $5M | $7.0B | $27.5B | $2.0B | $3.3B |
| Enterprise ValueMkt cap + debt − cash | -$4M | $7.1B | $26.7B | $2.2B | $3.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.28x | 143.59x | -127.79x | -14.66x | -39.90x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 61.74x | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 51.25x | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.95x | 9.43x | 11.94x | 3.11x | 23.76x |
| Price / BookPrice ÷ Book value/share | 0.34x | 3.32x | 15.51x | 5.86x | 2.58x |
| Price / FCFMarket cap ÷ FCF | — | 74.17x | 252.31x | — | — |
Evenly matched — CLGN and RGEN and NTRA and NVCR each lead in 1 of 4 comparable metrics.
Profitability & Efficiency
RGEN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
RGEN delivers a 2.5% return on equity — every $100 of shareholder capital generates $2 in annual profit, vs $-131 for CLGN. NTRA carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), RGEN scores 7/9 vs CLGN's 1/9, reflecting strong financial health.
| Metric | CLGNCollPlant Biotech… | RGENRepligen Corporat… | NTRANatera, Inc. | NVCRNovoCure Limited | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -130.7% | +2.5% | -15.1% | -50.8% | -5.9% |
| ROA (TTM)Return on assets | -86.3% | +1.8% | -10.4% | -16.5% | -4.6% |
| ROICReturn on invested capital | -2.7% | +2.2% | -36.1% | -16.4% | -31.1% |
| ROCEReturn on capital employed | -74.0% | +2.2% | -18.3% | -28.9% | -33.3% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 7 | 5 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.23x | 0.33x | 0.13x | 0.85x | 0.24x |
| Net DebtTotal debt minus cash | -$9M | $124M | -$862M | $187M | -$1M |
| Cash & Equiv.Liquid assets | $12M | $566M | $1.1B | $103M | $295M |
| Total DebtShort + long-term debt | $3M | $690M | $214M | $290M | $294M |
| Interest CoverageEBIT ÷ Interest expense | -70.95x | 2.64x | -34.29x | -96.80x | 1.08x |
RGEN leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,442 today (with dividends reinvested), compared to $291 for CLGN. Over the past 12 months, BEAM leads with a +87.4% total return vs CLGN's -77.9%. The 3-year compound annual growth rate (CAGR) favors NTRA at 54.1% vs CLGN's -61.2% — a key indicator of consistent wealth creation.
| Metric | CLGNCollPlant Biotech… | RGENRepligen Corporat… | NTRANatera, Inc. | NVCRNovoCure Limited | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -72.8% | -24.9% | -15.1% | +36.4% | +19.1% |
| 1-Year ReturnPast 12 months | -77.9% | -3.4% | +19.5% | +2.6% | +87.4% |
| 3-Year ReturnCumulative with dividends | -94.2% | -21.1% | +265.8% | -74.2% | -3.1% |
| 5-Year ReturnCumulative with dividends | -97.1% | -29.5% | +114.4% | -90.2% | -49.6% |
| 10-Year ReturnCumulative with dividends | -95.5% | +358.2% | +1834.7% | +38.5% | +72.4% |
| CAGR (3Y)Annualised 3-year return | -61.2% | -7.6% | +54.1% | -36.4% | -1.0% |
NTRA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CLGN and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
CLGN is the less volatile stock with a 0.89 beta — it tends to amplify market swings less than NVCR's 2.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 89.2% from its 52-week high vs CLGN's 8.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CLGNCollPlant Biotech… | RGENRepligen Corporat… | NTRANatera, Inc. | NVCRNovoCure Limited | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.89x | 1.71x | 1.17x | 2.15x | 2.08x |
| 52-Week HighHighest price in past year | $4.98 | $175.77 | $256.36 | $20.06 | $36.44 |
| 52-Week LowLowest price in past year | $0.28 | $109.52 | $131.81 | $9.82 | $15.35 |
| % of 52W HighCurrent price vs 52-week peak | +8.1% | +70.3% | +75.8% | +89.2% | +88.7% |
| RSI (14)Momentum oscillator 0–100 | 44.1 | 55.9 | 59.8 | 70.9 | 57.7 |
| Avg Volume (50D)Average daily shares traded | 90K | 911K | 1.4M | 1.4M | 2.0M |
Evenly matched — CLGN and NVCR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: RGEN as "Buy", NTRA as "Buy", NVCR as "Buy", BEAM as "Buy". Consensus price targets imply 87.3% upside for NVCR (target: $34) vs 26.3% for BEAM (target: $41).
| Metric | CLGNCollPlant Biotech… | RGENRepligen Corporat… | NTRANatera, Inc. | NVCRNovoCure Limited | BEAMBeam Therapeutics… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $163.67 | $265.63 | $33.50 | $40.83 |
| # AnalystsCovering analysts | — | 23 | 27 | 15 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RGEN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NTRA leads in 1 (Total Returns). 2 tied.
Best OverallRepligen Corporation (RGEN)Leads 2 of 6 categories
Loading custom metrics...
CLGN vs RGEN vs NTRA vs NVCR vs BEAM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is CLGN or RGEN or NTRA or NVCR or BEAM a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -95. 3% for CollPlant Biotechnologies Ltd. (CLGN). Repligen Corporation (RGEN) offers the better valuation at 143. 6x trailing P/E (61. 7x forward), making it the more compelling value choice. Analysts rate Repligen Corporation (RGEN) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CLGN or RGEN or NTRA or NVCR or BEAM?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +114. 4%, compared to -97. 1% for CollPlant Biotechnologies Ltd. (CLGN). Over 10 years, the gap is even starker: NTRA returned +1835% versus CLGN's -95. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CLGN or RGEN or NTRA or NVCR or BEAM?
By beta (market sensitivity over 5 years), CollPlant Biotechnologies Ltd.
(CLGN) is the lower-risk stock at 0. 89β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 141% more volatile than CLGN relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — CLGN or RGEN or NTRA or NVCR or BEAM?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus -95. 3% for CollPlant Biotechnologies Ltd. (CLGN). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to -133. 9% for CollPlant Biotechnologies Ltd.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CLGN or RGEN or NTRA or NVCR or BEAM?
Repligen Corporation (RGEN) is the more profitable company, earning 6.
6% net margin versus -32. 3% for CollPlant Biotechnologies Ltd. — meaning it keeps 6. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RGEN leads at 8. 1% versus -33. 5% for CLGN. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CLGN or RGEN or NTRA or NVCR or BEAM more undervalued right now?
Analyst consensus price targets imply the most upside for NVCR: 87.
3% to $33. 50.
07Which pays a better dividend — CLGN or RGEN or NTRA or NVCR or BEAM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CLGN or RGEN or NTRA or NVCR or BEAM better for a retirement portfolio?
For long-horizon retirement investors, Natera, Inc.
(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), +1835% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +1835%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CLGN and RGEN and NTRA and NVCR and BEAM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CLGN is a small-cap quality compounder stock; RGEN is a small-cap high-growth stock; NTRA is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(CLGN: 1825.0% · RGEN: 14.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.